Physician profile
Arphy Roy
NPI 1366953903
$709.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $46.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.52 | 2021-2022 | |
| Amgen INC. | $82.95 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $69.84 | 2021 | |
| Novo Nordisk INC | $60.17 | 2021 | |
| Lilly USA, LLC | $45.58 | 2021 | |
| Glaxosmithkline, LLC. | $38.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $34.34 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $26.56 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.94 | 2021 | |
| Dexcom, INC. | $19.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.77 | 2021 | |
| Pfizer INC. | $17.38 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arphy Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.